Uncategorized

Protalix BioTherapeutics, Inc. today announced that it is eligible to receive a $20 million milestone payment from its commercial partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group.

AdventHealth Tampa is proud to announce the accreditation of its new Obstetrics and Gynecology Residency Program, helping improve access to women’s healthcare in the Tampa Bay region.

The New England Journal of Medicine published detailed results from Eli Lilly and Company’s phase 2a study of peresolimab in rheumatoid arthritis, in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms.

SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, presented preliminary data from primate studies of AAV capsids that outperform the commonly used AAV9 capsid.

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, will present preclinical research showing the precise genome engineering of human B cells to express diverse therapeutic proteins using the company’s proprietary platform.

ImaginAb, Inc. announced lead selection and progression to IND-enabling studies of IAB56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors.

Adicet Bio, Inc. announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy taking place from May 16-20, 2023, in Los Angeles, CA.

Syngenta Group has withdrawn its STAR Market IPO application and will immediately apply for a public listing on the main board at the Shanghai Stock Exchange.

Chroma Medicine, Inc. announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform.

Revvity, Inc., announced a new license agreement with AstraZeneca for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.